GlassScriptPhysician profile
Ruhinder Singh
NPI 1710646013
$9,210.96
in general payments reported to CMS, 2019-2025
27 companies · $1,177 in 2025
The $1,177 reported for 2025 was more than what 89% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $2,993 · 2023: $3,138 · 2024: $1,904 · 2025: $1,177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,218.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,218.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,274.85 | 2022-2025 | Rexulti, Abilify Mycite, Abilify Asimtufii |
| Alkermes, INC. | $1,004.06 | 2022-2025 | Aristada, Lybalvi |
| Abbvie INC. | $868.18 | 2022-2025 | |
| Corium, LLC | $633.67 | 2022-2025 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $614.12 | 2022-2024 | Caplyta |
| Axsome Therapeutics, INC. | $572.64 | 2022-2025 | Auvelity |
| Lundbeck LLC | $458.67 | 2022-2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $447.44 | 2023-2025 | Qelbree, Qelbree |
| Teva Pharmaceuticals USA, INC. | $418.81 | 2022-2025 | Austedo Xr, Austedo, Austedo Xr |
| Neurocrine Biosciences, INC. | $372.45 | 2022-2024 | Ingrezza |
| Tris Pharma INC | $363.89 | 2022-2025 | Dyanavel Xr |
| Janssen Pharmaceuticals, INC | $357.05 | 2022-2025 | Spravato |
| Idorsia Pharmaceuticals US INC | $346.00 | 2022-2024 | Quviviq |
| Neos Therapeutics, LP | $305.25 | 2022-2025 | Adzenys Xr-Odt |
| Ironshore Pharmaceuticals INC. | $283.26 | 2022-2024 | Jornay Pm |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $233.59 | 2022-2025 | Trintellix |
| Bausch Health US, LLC | $219.88 | 2022-2025 | Aplenzin, Wellbutrin |
| Noven Therapeutics, LLC | $156.41 | 2023-2025 | Xelstrym, Secuado |
| Merck Sharp & Dohme LLC | $48.98 | 2022 | |
| Arbor Pharmaceuticals, INC. | $44.93 | 2022 | |
| Vanda Pharmaceuticals INC. | $37.02 | 2025 | Fanapt |
| Vertical Pharmaceuticals, LLC | $34.32 | 2023-2025 | Relexxii |
| E.R. Squibb & Sons, L.L.C. | $27.09 | 2025 | Cobenfy |
| Owp Pharmaceuticals, INC. | $25.55 | 2022 | |
| Collegium Pharmaceutical, INC. | $23.39 | 2025 | Jornay Pm |
| Avion Pharmaceuticals | $19.94 | 2023 | Methylphenidate Hydrochloride |
| Biogen, INC. | $19.52 | 2025 | Zurzuvae |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruhinder Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.